These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14732320)

  • 1. Low in vitro selection frequencies of enterococcal and staphylococcal mutants resistant to the oxazolidinone AZD2563.
    Stockdale MW; Tysall L; Johnson AP; Livermore DM; Woodford N
    Int J Antimicrob Agents; 2004 Jan; 23(1):88-91. PubMed ID: 14732320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
    Anderegg TR; Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2662-4. PubMed ID: 12121951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of Staphylococcus aureus and Enterococcus faecalis mutants with reduced susceptibility to the investigational oxazolidinone RWJ-416457.
    Santoro CM; Bush K; Abbanat D
    Int J Antimicrob Agents; 2010 Nov; 36(5):424-9. PubMed ID: 20846828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
    Johnson AP; Warner M; Livermore DM
    J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China.
    Tian Y; Li T; Zhu Y; Wang B; Zou X; Li M
    BMC Microbiol; 2014 Nov; 14():292. PubMed ID: 25420718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
    Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
    J Antimicrob Chemother; 2002 Aug; 50(2):271-6. PubMed ID: 12161411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZAAPS Program results for 2010: an activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries.
    Flamm RK; Farrell DJ; Mendes RE; Ross JE; Sader HS; Jones RN
    J Chemother; 2012 Dec; 24(6):328-37. PubMed ID: 23174097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
    Livermore DM; Mushtaq S; Warner M; Woodford N
    J Antimicrob Chemother; 2009 Apr; 63(4):713-5. PubMed ID: 19164418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin.
    Wang Y; Lv Y; Cai J; Schwarz S; Cui L; Hu Z; Zhang R; Li J; Zhao Q; He T; Wang D; Wang Z; Shen Y; Li Y; Feßler AT; Wu C; Yu H; Deng X; Xia X; Shen J
    J Antimicrob Chemother; 2015 Aug; 70(8):2182-90. PubMed ID: 25977397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.
    Chen H; Wu W; Ni M; Liu Y; Zhang J; Xia F; He W; Wang Q; Wang Z; Cao B; Wang H
    Int J Antimicrob Agents; 2013 Oct; 42(4):317-21. PubMed ID: 23880167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of the new oxazolidinone AZD2563 against Enterococci.
    Eliopoulos GM; Wennersten CB; Moellering RC
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3273-5. PubMed ID: 12234858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.
    Jones ME; Gesu G; Ortisi G; Sahm DF; Critchley IA; Goglio A;
    Clin Microbiol Infect; 2002 Feb; 8(2):101-11. PubMed ID: 11952723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of oxazolidinone and phenicol resistant enterococcal isolates from duck feces and carcasses.
    Na SH; Moon DC; Choi MJ; Oh SJ; Jung DY; Kang HY; Hyun BH; Lim SK
    Int J Food Microbiol; 2019 Mar; 293():53-59. PubMed ID: 30640000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-infection by two linezolid-resistant coagulase-negative staphylococci with two different resistance determinants.
    Mazzariol A; Kocsis E; Bragagnolo L; Pellizzer G; Rassu M; Cornaglia G
    Scand J Infect Dis; 2012 Dec; 44(12):978-81. PubMed ID: 22830638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.
    Livermore DM; Warner M; Mushtaq S; North S; Woodford N
    Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro.
    Wookey A; Turner PJ; Greenhalgh JM; Eastwood M; Clarke J; Sefton C
    Clin Microbiol Infect; 2004 Mar; 10(3):247-54. PubMed ID: 15008947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of linezolid-resistant CoNS isolates in Japan.
    Takaya A; Kimura A; Sato Y; Ishiwada N; Watanabe M; Matsui M; Shibayama K; Yamamoto T
    J Antimicrob Chemother; 2015 Mar; 70(3):658-63. PubMed ID: 25381168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tedizolid on clinical Enterococcus isolates: in vitro activity, distribution of virulence factor, resistance genes and multilocus sequence typing.
    Bai B; Hu K; Li H; Yao W; Li D; Chen Z; Cheng H; Zheng J; Pan W; Deng M; Liu X; Lin Z; Deng Q; Yu Z
    FEMS Microbiol Lett; 2018 Feb; 365(3):. PubMed ID: 29390078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005).
    Sader HS; Watters AA; Fritsche TR; Jones RN
    BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of a new cephalosporin, RWJ-54428, against streptococci, enterococci and staphylococci, including glycopeptide-intermediate Staphylococcus aureus.
    Swenson JM; Tenover FC
    J Antimicrob Chemother; 2002 May; 49(5):845-50. PubMed ID: 12003982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.